



Suggested Formula	Tacrolimus 0.15% Topical Ointment (Emulsion, 100 g)	FIN	F 004 426v3
-------------------	---	-----	-------------

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Tacrolimus, USP	TBD					
Propylene Glycol, USP	5.0	mL				
Medisca Ointment Base (Emulsifying)	TBD					

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

Hygroscopic (protect from moisture whenever possible):	Propylene Glycol
Light sensitive (protect from light whenever possible):	Tacrolimus, Propylene Glycol
Heat Sensitive (protect from heat whenever possible):	Tacrolimus
Narrow Therapeutic Index	Tacrolimus

Suggested Preparatory Guidelines

Non-Sterile Preparation Sterile Preparation

Processing Error / Testing Considerations: To account for processing error considerations during preparation, it is suggested to measure an additional **5 to 9%** of the required quantities of ingredients.

Special Instruction: Protective apparel, such as a lab coat, disposable gloves, eyewear and face-masks should always be worn.

Tacrolimus has a Narrow Therapeutic Index.

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



Suggested Formula	Tacrolimus 0.15% Topical Ointment (Emulsion, 100 g)	FIN	F 004 426v3
-------------------	---	-----	-------------

SUGGESTED PREPARATION (for 100 g)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor ^(*) : _____	Processing Error	Qty. to measure
Tacrolimus, USP §	TBD				
Propylene Glycol, USP §	5.0	mL			
Medisca Ointment Base (Emulsifying)	TBD				

* Takes into account increased batch size conversions and density conversions, if required.

§ Weigh / measure just prior to use.

Preparatory Instruction

1. Ingredient quantification:

A. Determine the potency of Tacrolimus based on the certificate of analysis:

	100%
MINUS	
Water Content (from certificate of analysis)	_____ %
DIVIDED BY	100
EQUALS	
Quantity of water free Tacrolimus, in decimal	_____
MULTIPLY BY	
Assay on anhydrous basis result (from certificate of analysis)	_____ %
DIVIDED BY	100
EQUALS	
i. Potency of Tacrolimus, in decimal	_____



Suggested Formula	Tacrolimus 0.15% Topical Ointment (Emulsion, 100 g)	FIN	F 004 426v3
-------------------	---	-----	-------------

2. **Ingredient quantification:**

A. Determine the quantity (in g) of Tacrolimus to make a Tacrolimus 0.15% Topical Ointment, batch size (100 g):

Quantity of Tacrolimus required for 100 g	0.150 g
DIVIDED BY	
Potency of Tacrolimus (Step 1Ai)	_____
EQUALS	
i. Quantity of Tacrolimus needed for 100 g	_____ g
MULTIPLIED BY	
Processing error adjustments (5 to 9%)	1.05 to 1.09
EQUALS	
ii. Quantity of Tacrolimus needed <i>plus</i> processing error adjustments	_____ g



Suggested Formula	Tacrolimus 0.15% Topical Ointment (Emulsion, 100 g)	FIN	F 004 426v3
-------------------	---	-----	-------------

3. **Ingredient quantification:**

A. Determine the actual quantity of Ointment Base (Emulsifying) to weigh for the required batch size (100 g):

Total Weight of the batch	100.00 g
MINUS	
Total amount of other ingredients except Tacrolimus	5.19 g
MINUS	
The weight of Tacrolimus (Step 2Ai)	_____ g
EQUALS	
i. Quantity Ointment Base (Emulsifying) needed for 100 g	_____ g
MULTIPLIED BY	
Processing error adjustments (5 to 9%)	1.05 to 1.09
EQUALS	
ii. Weight of Ointment Base (Emulsifying) required <i>plus</i> processing error adjustments	_____ g

4. **Powder-liquid preparation:**

A. Triturate the Tacrolimus (amount determined in Step 2Aii) to form a fine, homogeneous powder.

B. Incrementally add the fine, homogeneous powder (Step 4A) to the Propylene Glycol.

Specifications: Continuously mix until all solid particles have completely dissolved.

End result: Homogeneous liquid-like solution.



Suggested Formula	Tacrolimus 0.15% Topical Ointment (Emulsion, 100 g)	FIN	F 004 426v3
-------------------	---	-----	-------------

5.	<p><u>Medium integration:</u></p> <p>A. By geometric addition, combine and mix the following ingredients together:</p> <ul style="list-style-type: none"> -Homogeneous liquid-like solution (Step 4B) -Ointment Base (Emulsifying) (amount determined in Step 3Aii) <p><u>Specifications:</u> Continuously mix, using high-shear mixing techniques.</p> <p><u>End result:</u> Homogeneous ointment-like dispersion.</p>
6.	<p><u>Product transfer:</u></p> <p>Transfer the final product into the specified dispensing container (see “Packaging Requirements”).</p>

SUGGESTED PRESENTATION

Estimated Beyond-Use Date	30 days, as per USP.	Packaging Requirements	Tightly closed, light-resistant ointment jar/tube.	
Auxiliary Labels	1	Use as directed. Do not exceed prescribed dose.	6	Keep at room temperature (20°C – 23°C).
	2	Keep out of reach of children.	7	For external use only.
	3	Cap tightly after use.	8	Do not take with alcohol, sleep aids, tranquilizers or other CNS depressants.
	4	May impair mental and/or physical ability. Use care when operating a car or machinery.	9	Protect from light.
	5	Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use.	10	Keep in a dry place.
Pharmacist Instructions	Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.			
Patient Instructions	Contact your pharmacist in the event of adverse reactions.			



Suggested Formula	Tacrolimus 0.15% Topical Ointment (Emulsion, 100 g)	FIN	F 004 426v3
-------------------	---	-----	-------------

REFERENCES

1.	Ointments, Creams, and Pastes. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Third Edition</i> . American Pharmaceutical Association; 2008: 235.
2.	Propylene Glycol. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 6th Edition</i> . American Pharmaceutical Association; 2009: 592.
3.	Tacrolimus. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36th Edition</i> . London, England: The Pharmaceutical Press; 2009: 1843.
4.	Tacrolimus (Monograph). In: O'Neil MJ. <i>The Merck Index 14th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #9025.
5.	Tacrolimus. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations, 4th Edition</i> . American Pharmaceutical Association; 2009: 526.
6.	Tacrolimus Systemic. Thomson Micromedex. <i>USP DI – Drug Information for the Health Care Professional, 26th Edition</i> . Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 2745.
7.	USP <795>. <i>United States Pharmacopeia XXXII / National Formulary 27</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2009: 314.

DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.